New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

In older adults with cardiovascular disease, SGLT2 inhibitors significantly reduced the risk for the composite outcome of hospitalization or urgent visits for heart failure and cardiovascular death.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Identifying three high-risk prediabetes types can help physicians decide when to add metformin, GLP-1/GIP agents, or SGLT2 ...

Uptake of sodium-glucose cotransporter 2 (SGLT2) inhibitors among US patients eligible for treatment according to clinical guidelines is extremely low, no matter their diabetes status, according to ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve ...

Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...